The current rules for approved medicines
As of November 14, 2026, WADA does not prohibit semaglutide, tirzepatide, or liraglutide. The agency monitors semaglutide and tirzepatide in and out of competition to track potential patterns of misuse. The published 2027 program continues monitoring both drugs.[1][2][3][4]
Investigational drugs require a separate check
The retatrutide approval and trial guide explains why an investigational drug falls into a different regulatory situation. WADA’s S0 category prohibits pharmacological substances without approval for human therapeutic use when they are not covered by another category. A substance can fall under S0 without being named. Ask your anti-doping organization to confirm the status of any investigational product.[1][3][5]
What the studies measured
Weight change alone cannot tell an athlete how a medicine will affect training or performance. Research on lean mass during GLP-1 treatment explains what body-composition studies can measure. A 2026 narrative review found no consistent evidence of a performance benefit in humans.[6]
Check the exact medicine with your anti-doping organization before competition. Use the WADA list in force on the event date, and tell your prescriber that you compete under anti-doping rules.